NCT05110157已完成3 期
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 442
- 试验地点
- 87
- 主要终点
- Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to Week 10
研究概览
简要总结
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
详细描述
Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine when administered orally once daily as adjunctive treatment in participants with schizophrenia who have had an inadequate response to antipsychotics. The study will enroll approximately 400 participants with a diagnosis of schizophrenia. The expected duration of study participation for each participant is approximately 16 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must meet all of the following inclusion criteria:
- •Completed written informed consent.
- •At the time of signing the informed consent, participant must be ≥18 years of age
- •Medically confirmed diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
- •The initial diagnosis of schizophrenia must be ≥1 year before the screening visit.
- •Plasma levels for at least 1 of the participant's antipsychotic medications must be detectable by an available assay.
- •The participant is treated with a stable regimen antipsychotic medication.
- •Must meet all of the following criteria at the screening visit and Day 1:
- •PANSS total score ≥70
- •PANSS score of ≥4 on at least 1 of the following:
- •P1 (delusions)
- •P3 (hallucinations)
- •P6 (suspiciousness)
- •G9 (unusual thought content)
- •CGI-S score ≥4
- •Stable background antipsychotic medication dose between the screening visit and Day 1
- •Stable PANSS total score between the screening visit and Day 1
- •The participant is outpatient with stable symptomatology
- •The participant must have an adult informant (for example, a family member, relative, partner, social worker, caseworker, residential facility staff, or nurse).
- •Female participants of childbearing potential must agree to use contraception consistently from the screening visit until 30 days after the last dose of study drug or final study visit, whichever is longer.
- •Male participants must agree to use contraception consistently from screening until 30 days after last dose of study treatment.
排除标准
- •Participants will be excluded from the study if they meet any of the following criteria:
- •Pregnant or breastfeeding or plans to become pregnant during the study. This criterion must be reconfirmed prior to the first dose of study treatment on Day
- •Known hypersensitivity to any component of the formulation of valbenazine.
- •Has history of treatment resistant schizophrenia.
- •Evidence of depression as measured by a Calgary Depression Scale for Schizophrenia (CDSS) score ≥11 at the screening visit or Day
- •Participants with any suicidal behavior or suicidal ideation within 6 months before the screening visit or Day
- •Diagnosis of moderate or severe substance use disorder within the 6 months before the screening visit.
- •Have a clinically significant unstable medical condition within 60 days before the screening visit in the judgement of the investigator or any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit.
- •Prior (within 6 months of the screening visit) or concomitant use of any VMAT2 inhibitor.
研究组 & 干预措施
Vesicular monoamine transporter 2 (VMAT2) inhibitor
Experimental
Valbenazine once daily
干预措施: Valbenazine (Drug)
Placebo
Placebo Comparator
Placebo once daily.
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to Week 10
时间窗: Baseline to week 10
次要结局
- Change in Clinical Global Impression of Severity (CGI-S) score from baseline to Week 10(Baseline to week 10)
- Change in Personal and Social Performance Scale (PSP) score from baseline to Week 10(Baseline to week 10)
研究者
研究点 (87)
Loading locations...
相似试验
终止
3 期
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for SchizophreniaSchizophreniaNCT05654870Neurocrine Biosciences8
已完成
3 期
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyDyskinesiaCerebral PalsyNCT05206513Neurocrine Biosciences86
招募中
2 期
Efficacy of Valbenazine for the Treatment of Trichotillomania in AdultsTrichotillomania (Hair-Pulling Disorder)NCT05207085Yale University20
已完成
3 期
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)Angina PectorisCoronary Artery DiseaseNCT01442038Gilead Sciences2,651
已完成
3 期
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes SubjectsType2 Diabetes MellitusNCT03259789Theracos351